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Abstract
Paediatric HIV-1 infection remains a major problem for sub-Saharan Africa with over 
1300 new infections daily. Infected children have a high mortality with 50% dying by 
2 years of age. Access to antiretroviral therapy (ART) has significantly reduced the 
morbidity and mortality rates, however, appropriate monitoring of response to 
treatment remains a challenge. 
 
Objectives The studies included in this thesis were designed to: 1) describe the natural 
history of a cohort of HIV infected Ugandan children; 2) determine if the Total 
Lymphocyte Count (TLC) could be used as a surrogate marker for death in infected 
children; 3) document the growth, immune and virological response to antiretroviral 
therapy; and to: 4) document the antiretroviral treatment outcome of children exposed 
and not exposed to single dose nevirapine (sdNVP) at birth. 
 
Methods Cohort 1 (n=128) included infected children from the perinatal HIV 
prevention trial (HIVNET012) who were followed from birth to 5 years of age. 
History and physical examinations were conducted at birth, 6, 10 and 14 weeks, at 6, 
12 and 18 months and every following 6 months. CD4% and HIV-1 RNA were 
measured at birth, 14 weeks, 12 months, and every 6 months thereafter (Papers I & II). 
Cohort 2 (n= 124) included HIV-1 infected children who were initiated on ART and 
followed for a minimum of 48 weeks. CD4% and HIV-1 RNA were measured at 
baseline and 12, 24, 36 and 48 weeks after starting ART (Paper III). Children were 
classified into virological (V) and immunological (I) treatment success(S) or failure 
(F) (Paper III). A subset of children (n=92) exposed to NVP (at birth) at a median of 
1.7 years prior to ART and not exposed to NVP were initiated on NVP-based ART 
regimen and followed for 48 weeks (Paper IV). The data was analyzed to determine 
factors associated with survival and treatment outcome.  
 
Results The infected children had a very high mortality rate with 56/128 (42%) and 
70/128 (55%) dying by 2 and 5 years of age, respectively. Time to death was not 
statistically different for those infected in utero compared to those infected later when 
estimated from time of HIV acquisition. The leading causes of death were pneumonia, 
diarrhoea and malaria, similar to the uninfected children. There was a rapid decline in 
CD4% in the first 6 months of life and then a plateau but the HIV-1 RNA levels 
remained high (5.5 log10) throughout the 5 year follow-up (Paper I). The TLC did not 
correlate with the CD4 cell count (r = 0.01) or predict death in the next 12 months, 
when the WHO TLC thresholds were used (Paper II). Over 85 % (107/ 124) of the 
children who initiated ART had an undetectable viral load after 48 weeks of therapy. 
Those who initiated ART below 3 years of age had a greater increase in weight and 
height and those children with CD4 % > 15% at ART initiation were more likely to 
achieve treatment success(Paper III). Baseline CD4 %, age and WHO stage were the 
baseline factors associated with successful treatment outcome (Paper III). In the sub-
study (n=92), after 48 weeks on ART, 75% (33 /44) and 78% (35/44) of the children 
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exposed and not exposed to sdNVP had an undetectable viral load (< 400 copies/ml), 
respectively (p=0.8, Paper IV). 
 
Conclusion From the studies included in this thesis, we established that HIV infected 
Ugandan children had a very high mortality rate in the first 2 years of life, regardless 
of time of HIV acquisition. The TLC was not an appropriate surrogate marker for 
death and therefore could not be used to determine which children needed ART. Early 
initiation of ART was critical to ensure adequate growth and ARV treatment success. 
Older children exposed to sdNVP at birth benefited from a NVP based regimen and 
should not be denied access to ART when protease inhibitors (PI) are unavailable.  
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Introduction
There are an estimated 2 million children worldwide living with the human 
immunodeficiency virus -1 (HIV-1) and 90% reside in sub-Saharan Africa [1]. 
Mother-to-child transmission of HIV (MTCT) remains the major mode of acquisition 
of HIV-1 infection in children with 400,000 new infections each year [1]. In resource-
limited settings infected children have an extremely high mortality with 50% dying by 
2 years of age [2]. These children die from common childhood infections including 
pneumonia, malaria and diarrhoea. Over the last 5 years there has been increasing 
access to antiretroviral therapy (ART) for people living with HIV/AIDS in low-income 
countries. However, < 10% of the 3 million people on ART world wide are children 
[1]. Access to antiretroviral treatment for children lags behind adults because of the 
limited paediatric antiretroviral drug formulations, complexity of prescribing 
antiretroviral therapy (ART) in children and an inadequate number of health care 
workers trained to provide paediatric ART services [3]. 
 
Uganda has ~ 1 million people living with HIV-1, 150,000 of whom are children [1]. 
Without access to prevention of mother to child HIV transmission (PMTCT) services, 
an estimated 20,000 new infections occur through MTCT each year in Uganda [4]. 
Similar to HIV-1 infected children from other resource-limited settings, Ugandan 
infected children have a very high mortality [5]. Using the current WHO 
recommendations for ART initiation, about 76,750 children are eligible for ART [4, 
6]. Currently, 19,954 children are on ART which accounts for only 26 % of the 
children who require ART and 8 % of all individuals on ART in Uganda [4]. The 
number of children on ART in Uganda falls below the WHO recommended target of 
10% of the total population on ART. This thesis presents the natural history of HIV-1 
infected children from the perinatal HIV prevention trial HIVNET012, the utility of 
the TLC for predicting death in infected children and the early response to 
antiretroviral therapy (ART) in a cohort of HIV-1 infected Ugandan children.  
Natural history of HIV-1 infection in African children 
The high HIV-1 seroprevalence in pregnant women from sub-Saharan Africa 
continues to drive the paediatric HIV-1 epidemic (1). Prior to the introduction of 
PMTCT services 21-43 % of HIV-1 infected women in Africa transmitted HIV-1 
infection to their infants compared to 14-25% in high-income countries [7, 8]. 
Advanced maternal disease and almost universal breastfeeding contribute to the higher 
vertical transmission rates in Africa [7]. Despite significant breakthroughs in PMTCT 
research, along with WHO and country-specific guidelines for implementation of 
PMTCT services in antenatal clinics only 50% of the pregnant women worldwide are 
receiving them [1]. As many pregnant women are unaware of their HIV status, their 
infants remain at high risk of acquiring HIV-1 infection during pregnancy and 
lactation.  
 
Without antiretroviral treatment, HIV-1 infected children in resource-limited settings 
have a mortality rate of 45-59% by 2 years of age, compared with 10-20% in Europe 
and USA [9-13]. Those infants who quickly progress to AIDS and die before 2 years 
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of age are considered rapid progressors compared to those children surviving beyond 2 
years and progress more slowly to AIDS and death [13]. A bimodal disease pattern has 
been well documented in paediatric HIV-1 birth cohorts from Europe and United 
States of America, with those infants infected in utero having a more rapid disease 
progression compared to those infected later [9, 14].  Similar data has been reported 
from Africa but most of the cohorts only have follow-up for the first 2 years of life.  A 
small Rwandan cohort of infected children followed for 5 years showed a 5-fold 
higher risk of death for children infected in the first 3 months of life compared to those 
who acquired the infection later, suggesting that children infected earlier were more 
likely to be rapid progressors [10]. Of the 54 children who were infected and followed 
for 5 years, 17%, 28% and 35% developed AIDS symptoms by 1, 2 and 5 years 
respectively. Among the 28 children who died, only 9 had symptoms of AIDS and the 
median time of survival after the onset of AIDS was 9 months (IQR 4-21 months). In a 
Malawi cohort of infected children, 35% died by 2 years of age and 45% and 20% 
were in CDC clinical category B and C, respectively. By 3 years of age, 89% had died 
and the 10% who were alive were in CDC clinical category B or C, with only 1% 
asymptomatic [15]. In a report from West Africa, infants who became HIV infected 
before 12 days and between 13 and 45 days of age had a higher risk of dying 
compared to those infected after 45 days, with relative hazards of 18.0 (CI 4.8-69) and 
7.6 (CI 2.0 -29.5), respectively [11]. In contrast, in the European collaborative study 
15% of the children progressed to CDC category C or death by 1 year of age, 40% by 
5 years and 50% by 10 years. Those children born after 1995, had a significantly 
reduced mortality rate of 5% at 12 months of age because of access to ART [16].  
 
Prior to use of antiretroviral therapy, the median survival of infected children from 
Europe and USA was 8 years compared to 2 years in resource-limited settings [2]. The 
high numbers and early mortality in infected children from resource-limited settings is 
due to severe recurrent infections, malnutrition, host immunity, HIV-1 subtype, 
poverty and limited access to quality health-care [17-20]. Co-infections are associated 
with immune activation and stimulation of CD4 cells which leads to increased 
replication of  HIV-1, increase in viral load and disease progression [21, 22]. Like 
previous reports from the USA, African children with a higher viral load (> 250,000 
copies/ml) and lower CD4 cell count (< 15%) had a higher risk of death [15, 23]. 
Maternal factors including high viral load, low CD4 cell count and death also 
contribute to the mortality in HIV-1 infected children [13]. 
 
HIV-1 infected African children have a 10-fold increased childhood mortality risk 
compared to uninfected children [24]. The causes of morbidity and mortality in the 
infected children are similar to those children who are uninfected including, 
pneumonia, malaria and diarrhoea. The HIV-1 infected child tends to have more 
severe infections, with a slower recovery and response to treatment [25]. The African 
child has multiple inter-current infections, underlying malnutrition and micronutrient 
deficiencies that also contribute to the high mortality [26].  
 
Various cohorts of infected children from African countries have demonstrated a high 
mortality in the first 2 years of life. A cohort study in Kenya found the 2-year 
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mortality rate from a randomized controlled trial of breastfed vs. formula-fed infants 
was similar, at 46% and 40%, respectively [27]. The formula-fed infants had a 
significantly reduced HIV-1 transmission rate, but had a high mortality rate mainly 
due to diarrhoeal disease and malnutrition. In Uganda, a rural community cohort of 
HIV-1 exposed children followed for 2 years reported a mortality rate of 54.7% in 
HIV-1 infected children compared to 16.6% in uninfected children [28]. In West 
Africa, there was a child mortality rate of 51% at 18 months in a cohort of infected 
children whose mothers had been randomized to zidovudine or placebo for PMTCT. 
The diagnosis of HIV-1 infection before 12 and between 13 and 45 days, clinical 
AIDS, maternal viral load, maternal CD4 cell count and survival were risk factors for 
child death [11]. In contrast, a study from Durban, South Africa, reported a 2-year 
mortality rate of 19% in HIV-1 infected children who were exclusively breastfed. This 
reduced 2-year mortality rate noted in the Durban cohort compared to the other cohorts 
of infected African children may be related to access to quality health care services, 
regional differences in the child mortality rate, the higher rate of exclusive 
breastfeeding and HIV-1 subtype [2, 29].  
Table 1. Mortality in HIV-1 infected children from African countries 
Country Predominant 
subtype in 
country 
Study design Infected 
children 
(n) 
Age of 
mortality 
estimation 
Mortality 
Rwanda 
(Spira R [10]) 
A & D Observational 94 2 years 45%  
Kenya 
(Nduati R [27]) 
A & D Clinical trial  
Randomized  
BF vs. FF 
197 2 years 46% 
Uganda 
(Brahmbhatt 
[28]) 
A & D Observational 69 2 years 54% 
South Africa 
(Bobat R [29]) 
C Observational 
BF vs. FF 
43 2 years 39% 
Malawi, 
Zambia 
Tanzania*  
(Chilongozi[30]) 
C 
 
A & D* 
Observation  
cohort 
HPTN 024 
404 12 months 42% 
West Africa 
Cote d’Ivoire 
& Burkina 
Faso (Dabis 
F[11]) 
A & G 
CRF02_AG 
Clinical trial 
Randomized  
AZT vs. 
placebo 
100 18 months 51% 
 
The high mortality rate of HIV-1 infected children from sub-Saharan Africa is similar 
across the continent, albeit slightly lower in South Africa (Table 1). The risk factors 
for early infant mortality include early acquisition of HIV-1 infection, progression to 
clinical AIDS and maternal health and survival [2, 11, 13]. Without access to 
antiretroviral therapy this high and early mortality rate of HIV-1 infected children will 
persist in resource-constrained settings. The scale-up of PMTCT is critical for 
prevention of new paediatric infections, but also provides an opportunity to identify 
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HIV-1 infected infants early and refer them to appropriate care and treatment services 
[2]. 
 
Clinical features and diagnosis of paediatric HIV-1 infection
The clinical features of AIDS in both adults and children are related to the severe 
immune deficiency associated with HIV-1 infection. Children present with recurrent 
and severe common childhood bacterial infections including pneumonia, otitis media, 
sinusitis, septicaemia and meningitis. In addition, lymphadenopathy, hepatomegaly, 
splenomegaly and malnutrition that presents with failure to thrive, stunting and severe 
acute malnutrition are also common  features of  infected children from resource-
limited settings [2, 17]. In sub-Saharan Africa, 40–50% of children admitted to 
hospital with severe acute malnutrition are HIV-1 infected [31]. Co-infection with 
tuberculosis is common in HIV-1 infected children in Africa because of  increased 
exposure to TB from HIV-1 co-infected adults in the home and the higher risk of 
disease progression after acquisition of  primary TB infection [32]. As HIV-1 infection 
progresses to AIDS the children develop other opportunistic infections and conditions 
including Pneumocystis jorveci pneumonia, cryptococcal meningitis in older children, 
herpetic and cytomegalovirus infections and HIV-1 associated cancers e.g. kaposi 
sarcoma. Therefore a child presenting with signs and symptoms suggestive of HIV-1 
infection including recurrent bacterial infections, tuberculosis and/or severe acute 
malnutrition should be tested for HIV-1 to determine its HIV status and ensure 
appropriate referral for care and treatment. With increased access to early ART, many 
of these clinical features are becoming less prevalent in infected children. 
All infants born to HIV-1 infected women passively acquire maternal IgG antibodies 
across the placenta during the third trimester of pregnancy, and therefore test positive 
using routine HIV-1 antibody tests. In the majority of HIV-1 exposed but uninfected 
infants, the maternal HIV-1 antibodies decay by 9-12 months of age. All uninfected 
children will lose maternal antibodies by 18 months of age and therefore will test HIV-
1 negative using routine rapid antibody tests [33]. Infected infants remain HIV-1 
antibody positive after 18 months of age, as they develop their own viral-specific HIV 
antibodies. Because all HIV-1 exposed infants are antibody positive, the diagnosis of 
HIV-1 infection in infancy requires viral-specific tests such as ultra sensitive HIV-1 
p24 antigen, HIV-1 DNA PCR or RNA PCR [34, 35]. The diagnosis of HIV-1 in 
infancy remains a challenge in resource-limited settings where access to these viral 
tests is limited. However, many countries in sub-Saharan Africa are setting up early 
infant diagnosis (EID) programs using dried blood spots for HIV-1 DNA PCR testing 
at reference laboratories [33, 35].  
Classification of HIV-1 infection in both adults and children has relied on clinical 
features, specific opportunistic infections and CD4 cell count. The CDC clinical 
criteria classifies children into 3 groups, A-asymptomatic, B-symptomatic and C-
symptomatic with AIDS. However, the CDC classification system had limitations as 
many of the listed diseases needed advanced diagnostic technology and some of the 
conditions common in resource-limited settings were not included.  
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Table 2. WHO Clinical Staging of HIV for infants and children with established 
HIV-1 infection.[40]
Clinical Stage 1
- Asymptomatic 
- Persistent generalized lymphadenopathy 
Clinical Stage 2
- Unexplained persistent hepatosplenomegaly 
- Papular pruritic eruptions 
- Extensive wart virus infection 
- Extensive molluscum contagiosum 
- Recurrent oral ulcerations 
- Unexplained persistent parotid enlargement 
- Lineal gingival erythema 
- Herpes zoster 
- Recurrent or chronic upper respiratory tract 
infections
  (otitis media, otorrhoea, sinusitis, tonsillitis) 
- Fungal nail infections 
Clinical Stage 3
- Unexplained persistent hepatosplenomegaly 
- Papular pruritic eruptions 
- Extensive wart virus infection 
- Extensive molluscum contagiosum 
- Recurrent oral ulcerations 
- Unexplained persistent parotid enlargement 
- Lineal gingival erythema 
- Herpes zoster 
- Recurrent or chronic upper respiratory tract 
infections
  (otitis media, otorrhoea, sinusitis, tonsillitis) 
- Fungal nail infections 
 
Clinical Stage 4
- Unexplained severe wasting, stunting or severe  
  malnutrition not responding to standard therapy 
- Pneumocystis pneumonia 
- Recurrent severe bacterial infections (e.g. empyema,  
  pyomyositis, bone or joint infection, meningitis, but 
  excluding pneumonia) 
- Chronic herpes simplex infection; (orolabial or 
cutaneous
  of more than one month’s duration, or visceral at any  
  site) 
- Extrapulmonary TB 
- Kaposi sarcoma 
- Oesophageal candidiasis (or candiadisis of trachea,  
  bronchi or lungs) 
 -Central nervous system toxoplasmosis (after the  
  neonatal period) 
- HIV encephalopathy 
- Cytomegalovirus (CMV) infection; retinitis or CMV   
  infection affecting another organ, with onset at age more 
  than one month 
- Extrapulmonary cryptococcosis including meningitis 
- Disseminated endemic mycosis (extrapulmonary  
  histoplasmosisi, coccidioidomycosis, penicillosis) 
- Chronic cryptosporidiosis (with diarrhoea) 
- Chronic isosporiasis 
- Disseminated non-tuberculous mycobacterial infection 
- Cerebral or B-cell non-Hodgkin lymphoma 
- Progressive multifocal leukoencephalopathy 
- HIV-associated cardiomyopathy or nephropathy 
 
The WHO paediatric clinical staging developed for resource-limited settings consists 
of stage I - asymptomatic, stage II –mild symptoms, stage III- moderate symptoms and 
stage IV-severe symptoms with AIDS (Table 2).  In adults and children > 5 years of 
age, absolute CD4 cell count is used to monitor disease progression and level of 
immune suppression (Table 3). In children < 5 years of age CD4% is more reliable for 
assessing the degree of immune suppression. All infants are born with a high absolute 
CD4 cell count, regardless of HIV-1 status, experience a steady decline in CD4 cell 
count with age, until about 6 years of age when they reach adult levels [36, 37]. 
Therefore, infected children < five years of age are monitored using CD4% which is 
less age dependent and more reliable to determine degree of immune suppression 
(Table 3). 
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Table 3.WHO immunological classification for established infection in infants 
and children.[40]
HIV-associated 
immunodeficiency 
<11 months 
(CD4%) 
12-35 months 
(CD4%) 
36-59 months 
(CD4%) 
>5 years  
(CD4 count) 
None or not significant >35 >30 >25 >500 
Mild 30-35 25-30 20-25 350-499 
Advanced 25-29 20-24 15-19 200-349 
Severe  <25 <20 <15 <200 or 
<15% 

The CD4 cell count and viral load (HIV-1 RNA) are surrogate markers for disease 
progression in children and adults [6]. Peak and set-point plasma viral levels in infants 
are considerably higher than those in adults [38].  This difference in peak viraemia is 
most likely due to the immature immune system in infancy which poorly contains 
HIV-1 replication leading to higher levels of circulating virus and a more rapid disease 
progression in children [39]. Viral load testing is not readily accessible in most centres 
in Africa, and therefore weight and CD4% are used to monitor response to ART in 
most children in resource-limited settings [6].
Table 4. The immunological cut-offs for initiation of ART in children according 
to WHO Antiretroviral therapy guidelines 2006.[41]
 
Immune marker Age-specific recommendation to initiate ART 
  <12 months 12 - 35 months 36 - 59 months 5 years 
CD4 percent All <20% <20% <15% 
CD4 count/mm3 All <750 cells <350 cells <200 cells 
TLC/mm3 All <3000 cells <2500 cells <2000 cells 
Clinical criteria for ART – WHO clinical stage 3 and 4 
Identifying infected children at highest risk of disease progression and death is 
difficult in infancy because the CD4 cell count and HIV-1 RNA do not predict death 
[13]. In older children, the CD4 cell count remains the stronger predictor for death to 
determine which children are at highest risk and require ART. The CD4% is the main 
indicator for immune function that is used to determine which children require ART. 
The WHO developed age-appropriate CD4% cut-offs to guide health-workers in 
resource-limited settings about when to initiate ART (Table 4). 
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Antiretroviral therapy in resource-limited settings 
Access to antiretroviral therapy has made a significant difference in the lives of 
infected adults and children with decreased morbidity and mortality [3, 42, 43]. The 
improved survival and quality of life of children on treatment has been evident in high-
income countries since effective ART became available [44]. However, there remains 
a large gap in resource-constrained countries between the number of infected 
individuals that required ART and those who receive it. Currently only 42% of the 
2,700,000 HIV infected people in sub-Saharan Africa needing ART receive it, < 10% 
being children [1]. Only 37% and 28% of infected adults and children, respectively, 
who are eligible for ART are receiving treatment [45]. 
 
The initial costs of effective ART made the treatment prohibitive for the majority of 
infected people in resource-limited countries. In 2003, WHO set a target to treat 3 
million people from resource-limited settings with antiretroviral therapy by 2005 [46]. 
With support from Global Fund for AIDS, TB and Malaria, and the President’s 
Emergency Plan for AIDS Relief (PEPFAR), low-income countries started national 
treatment programs and finally made access to ART a reality in Africa. Recognizing 
that children were grossly underserved, UNICEF and its partners launched the global 
campaign ‘Unite for children, unite against AIDS’ in 2005, in an effort to increase 
HIV diagnosis and treatment of infected children and improve linkage to the already 
existing PMTCT programs [47].  
 
 
Figure 1. UNAIDS schema for optimizing antiretroviral therapy (UNAIDS Global HIV 
Report 2010). 
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Despite increased access to ART in resource-limited settings the coverage for children 
has lagged behind that of adults [45]. However, there have been some success stories 
where children initiated on ART in Africa have shown similar immunological and 
virological responses as their counterparts in Europe and USA [3, 48-51]. The 
challenges of providing ART for children include the lack of appropriate paediatric 
drug formulations, limited ARV drug choices, the need to adjust the drug doses 
according to a child’s weight, the inadequate number of well trained health-workers to 
prescribe and monitor therapy, as well as the overall complexity of delivering 
paediatric care and treatment. UNAIDS recognizes the complexity of delivering ART 
in resource-constrained settings and recommends the strengthening of the 5 pillars of 
treatment to improve services and treatment outcomes (Figure 1). 
Antiretroviral therapy in African children 
At the end of 2009, ~ 1.27 million children in sub-Saharan Africa were in need of 
ART, but only 354,000 were receiving ART, a coverage of 28% [1]. Most of the 
children initiated on antiretroviral treatment were over 5 years of age and had survived 
early childhood without ART [3, 51-53]. The majority of children were initiated on the 
WHO recommended first-line regimen of 2 nucleoside reverse transcriptase inhibitors 
(NRTIs), stavudine (d4T) or zidovudine (AZT) plus lamivudine (3TC), and one non-
nucleoside reverse transcriptase inhibitor (NNRTI), nevirapine (NVP) or efavirenz 
(EFV), as demonstrated by the UNAIDS survey from 36 countries (Figure 2). Initially, 
only adult fixed-dose ARV drug combinations were available and were also used for 
infected children with successful treatment outcomes [54, 55]. 
 
A review of over 30 cohorts of HIV infected children from Africa who were initiated 
on ART with a range of 50 to 4000 children per study was reported in 2008 [3]. At 
ART initiation the median age was 5 years and the median CD4 percent was 6 -15%. 
The majority of children were malnourished with weight for age (WAZ) and height for 
age (HAZ) scores less than -2 SD below normal. Mortality was < 10% in those 
children followed for 12 months with the majority of deaths occurring in the first 6 
months on therapy. 
 
Eleven centres used adult fixed dose combinations and the children were dosed 
according to weight bands. Over half of the studies documented an improvement in 
nutritional and clinical status with an average weight gain of 1.8–3.6 kg in the first 
year of treatment. The median CD4% increased significantly in the first year with a 
plateau after 12–18 months and the viral load decreased by ~ 2.0 log10 copies per ml 
within 1 year of starting therapy. The large number of children with malnutrition, older 
median age and very low CD4% at ART initiation has been documented in multiple 
paediatric treatment programs from Africa [3, 49, 53, 56]. With the scale-up of 
PMTCT, early infant diagnosis (EID) and the WHO recommendation to initiate ART 
in all infected children < 2 years of age, there is an opportunity for younger and more 
immune competent children to be initiated on ART [57]. 
 
Monitoring the response to antiretroviral therapy in resource-limited settings remains a 
challenge because laboratories that perform CD4 cell counts and HIV-1 RNA 
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measurements are limited to a few urban centres. Treatment programs in most African 
settings use weight and occasionally height with CD4%/counts where available, to 
monitor the response to ART. Children initiated on ART can achieve adequate growth 
and immune responses regardless of incomplete viral suppression [58, 59]. The 
children achieve normal weight for age z score within 6–12 months of ART but gain in 
height is often delayed [58]. It is difficult using only clinical monitoring to detect the 
emergence of resistant mutations and virological failure, which limits future treatment 
options. Therefore, low-cost point of care tests for CD4 cell count estimation and HIV-
1 RNA measurements are urgently needed in Africa. 
Figure 2. First line regimen in children from 36 low and middle income countries (n 
=177,064) December 2008 (UNAIDS scaling up ART) 
Adherence is the cornerstone to successful ART and requires the child to take >95% of 
the prescribed ARV drugs [60, 61]. The emergence of resistant mutations when 
children on ART fail to completely suppress virus is well documented [51, 62, 63]. For 
children on ART for >48 weeks, HIV-1 resistant mutations have been reported in 20–
50 % of those children who fail to completely suppress virus. The most common 
resistance mutations identified through genotypic analysis, usually detected within 1-3 
months after failure, include M184V, which confers resistance to lamivudine and 
Y181and K103N confers resistance to NVP and EFV [64]. The T215F mutation for 
AZT tends to emerge later and may not be detected before 12 months of failure [65].
The longer children are maintained on a failing ART regimen the greater number of 
thymidine analogue mutations (TAMs) to emerge with an increased cross-class 
resistance [66, 67]. As more infants are exposed to NVP in infancy and other children 
fail their first-line ART regime, many more children will develop resistant mutations 
requiring a treatment switch. Second line ARV drugs are more expensive, tend to be 
more difficult to administer and have a higher pill burden. Therefore, it is critical that 
children and families are provided with ongoing counselling and support to enable 
infected children to maintain adequate viral suppression for as long as possible on their 
first-line regimen, in order delay the need to switch to second line therapy. 
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Response to NNRTI-based ART after nevirapine exposure at birth
With the scale-up of PMTCT, most HIV-1 infected infants who fail ART prophylaxis 
will have prior exposure to NVP with emergence of NNRTI resistant mutations, which 
do fade over time. [68]. Subsequent therapy with an NNRTI based regimen in infants 
exposed to sdNVP has been associated with higher rates of virological failure when 
compared to those infants not exposed to nevirapine (NVP) [69-71]. Therefore, WHO 
recommends that all infected infants exposed to NVP during the peripartum period, or 
during infancy, should be initiated on a protease inhibitor (PI) based regimen for 
prevention of breast milk transmission [6]. However, the scale-up of PI based 
regimens for these infants remains a challenge in many resource-limited countries 
because the accessible PI, lopinavir/ritonavir (LPV/r), is more expensive than the 
NRTIs and NNRTIs. In addition, the syrup formulation requires refrigeration and a 
tablet cannot be divided in half, making it difficult to administer to young infants.  
 
In a multi-centre randomized controlled trial of a PI vs. NNRTI regimen in children 
exposed to NVP at birth (P1060), the children in the NNRTI arm had a higher 
virological failure rate (44% vs. 20%) compared to the children in the PI arm. 
However, the median age was 0.7 years, making it impossible to determine if this 
virological failure rate would have been lower in older children if they had been 
followed for a longer period than the study endpoint of 24 weeks after ART initiation 
[70]. Of note, 60% of the children in the NNRTI arm did achieve complete viral 
suppression despite prior exposure to sdNVP. Therefore, where PIs are not accessible 
infected children may still benefit from a NVP-containing ART regimen and  should 
not therefore be denied ART. These recent study results are important for guiding 
recommendations for 1st line ART in Africa where many infected children will have 
had prior NVP exposure at birth as part of PMTCT.  
Paediatric antiretroviral therapy in Uganda
Access to free ART for children started in 2002/3 through donations from different 
philanthropic organizations. However, in 2006, through PEPFAR and Global Fund for 
TB, HIV and Malaria, ART became more widely available in Uganda for both adults 
and children. Children initiated on ART experienced a significant reduction in 
morbidity and mortality,  with an improvement in their overall quality of life [48, 51, 
72]. 
 
Of the 150,000 children living with HIV-1, ~75,000 require antiretroviral therapy but 
only 26% are receiving therapy (1). By 2010, Uganda had 248,200 individuals on 
ART, with 19,854 (8%) of them children under 15 years of age [73]. Of the 416 ART 
facilities providing ART in the country, only 296 also provide paediatric ART 
services. The majority of infected children on ART receive treatment from urban 
centres, with one third registered at clinics in Kampala, the capital city. The National 
ART guidelines recommend 2 NRTIs and 1 NNRTI as first line therapy for HIV-1 
infected children, except for those infants exposed to NVP, where a PI-based regimen 
is recommended, consistent with the current WHO ART guidelines for children [6, 
74].  
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The MOH recommends use of fixed-dose combination ARV drugs for children 
because they are cheaper than syrups, less bulky, easier for the caretaker to administer, 
and for the health-worker to monitor adherence [74]. The use of fixed-dose 
combinations for paediatric ART enables a significant reduction in the bulk of drugs 
dispensed to caregivers (Figure 3). Fixed-dose combination ARVs improve overall 
adherence and are more acceptable to care givers with young children [75]. However, 
there are no ARV fixed-dose combinations with LPV/r so that many of the infants on 
ART, outside the centres of excellence, are still initiated on a NVP based ARV 
regimen. The MOH is currently updating its national ART guidelines and improving 
the drug-supply chain management through the national medical stores (NMS). This 
should provide further guidance to the health-workers delivering ART services and 
prevent ARV stock outs at health units.  
 
 
Figure 3. Comparison of a month’s supply of first-line ART (A) syrups  (B) single 
tablets and (C) fixed-dose combination tablets [Photographs A & B – ARROW study, 
Mulago by Bethany Naidoo, Photograph C – MUJHU clinic]. 
 
The adherence rate to ART in children from a large HIV clinic in Kampala was much 
higher than reports from resource-rich settings with > 90 % of  the children having 
A 
B C
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good adherence when using the self report method [60, 76]. However, using an 
unannounced pill counts method, a much lower levels of adherence was found when 
compared to self report, 74% vs. 94%, respectively.  Children receiving ARV fixed- 
dose combinations achieve much higher levels of adherence compared to those 
children on syrup formulations [75]. Many of the children from the paediatric ART 
programs at centres of excellence (COE) in Uganda receive additional adherence 
counselling for their HIV infected children and care takers, which contributes to good 
adherence to ART.  In addition, in the family-based comprehensive HIV care program 
having the mother and the HIV infected family members all attending the same clinic 
and on the same day enabled similar messages to be shared with the family and for the 
different members to support each other to adhere to their medication [77]. It is not 
clear if this high level of adherence is maintained after being on ART for a long time, 
after improved health of the child and development of treatment fatigue by the 
caregiver. To improve adherence, there is an urgent need to increase the availability of 
various fixed-dose combination ARV regimens for children and develop innovative 
strategies for adolescents. 
 
Between 2004 and 2005 at the national referral hospital, Mulago, a cohort of 250 
children were initiated on ART; mean age of 9 years (SD 4.5) and a median CD4% of 
8.6% (3.5–12.7%). After 12 months of ART, 164/222 (74%) of the children had an 
undetectable viral load compared to 392/454 (86%) of the adult population but the 
children had a more robust immune response. Overall mortality was 28/250 (11%) 
with over 60% of deaths occurring in the first 3 months on therapy. The predictors of 
virological failure were CD4 percent < 5%, male child and being on a d4T-based 
regimen. All 8 samples that had genotype resistance testing done at 12 months 
documented NNRTI resistance and the 3TC-associated mutation (M184V) [51].  
Kiboneka et al documented their experience of 770 children initiated on ART and 
followed for a median duration of 377 days [48]. Similar to other reports from Africa, 
the children achieved a good clinical and immune response, with a low mortality rate 
of 2.3%. They noted very high levels of adherence in this cohort with 94% of the 
children achieving greater than 95% adherence to ART. However, orphans were noted 
to initiate ART at an older age, have a lower CD4 cell count and a more advanced 
WHO clinical staging. The adherence levels noted in this study were much higher than 
in other reports from Africa [60, 78]. Both these programs provided additional 
adherence counselling to support the children during ARV treatment.  
 
Adherence remains the major challenge to achieving a sustained response to 
antiretroviral therapy, and requires additional counselling and support for infected 
children, particularly for orphans who often have multiple care-givers. Significant 
improvement in appearance and growth has been documented in many children 
initiated on ART (Figure 4). 
 
Baylor College of Medicine Children’s Foundation Uganda (Baylor-Uganda) supports 
the paediatric HIV clinic at Mulago hospital, Kampala and several satellite clinics 
countrywide. PEPFAR has provided additional financial support through Baylor 
Uganda to expand paediatric HIV care and treatment services countrywide. Currently 
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the foundation has over 6900 infected children registered with 4000 of them on ART. 
The median age at ART initiation was 8 years in 2006 and has subsequently reduced to 
5 years of age. The outcome of paediatric ART is similar across the country with a 
significant increase in growth and CD cell count. About 70% of the cohort of children 
who had access to viral load monitoring have an undetectable viral load after 48 weeks 
of ART (A Kekitiinwa PIDC personal communication). In the Baylor Foundation 
Uganda supported ART clinics, over 80% of the children who initiated ART are still in 
follow-up but in contrast adherence to clinic visits across the country is much lower, 
with only 60% of the children initiated on ART still in follow-up after 60 months [4].  
 
Figure 4. A 12 year HIV-1 infected female child at MU-JHU before ART initiation and 
after one year of therapy. 
 
Despite the significant improvement in survival and quality of life on ART, the 
individual ARVs are associated with complications and toxicities. Children tend to 
experience fewer adverse side effects on ART compared to adults [51]. In Uganda, 
similar to reports from other African countries where children are on ART, < 5% of 
the children develop toxicities secondary to ART [50] . The commonly reported side 
effects include severe anaemia from AZT, hepatotoxicity and a rash from NVP, 
lipodystrophy from d4T/AZT, and dyslipidaemia usually from PIs. [50, 79]. Due to 
limited access to laboratory services that can provide routine haematology and 
chemistries toxicity monitoring, laboratory-based adverse events are only documented 
in children receiving ART at centres of excellence in Uganda. Children on ART must 
be closely monitored to ensure good adherence and, adequate clinical and 
immunological response to ART, in order to delay treatment failure, which limits 
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future treatment options. Without access to virological monitoring in most resource-
limited settings, adherence to the first-line ARV regimen is critical, in order to delay 
the need for more expensive second line regimens. 
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Aim and study objectives
Aim
The overall aim of this thesis was to describe the natural history of paediatric HIV-1 
infection in Uganda and document the early growth, immune and viral responses to 
highly active antiretroviral therapy in HIV-1 infected children including those children 
exposed to single dose nevirapine at birth. 
Specific objectives 
 
1. To describe the natural history of a cohort of perinatally HIV-1 infected 
children from birth to five years of age. (Paper 1) 
 
2. To determine the utility of the total lymphocyte count (TLC) as a surrogate 
marker for risk of death in HIV-1 infected Ugandan children. (Paper II) 
 
3. To document the growth response to antiretroviral therapy and determine 
clinical factors associated with successful antiretroviral treatment outcome. 
(Paper III) 
 
4. To determine the response to a NVP containing ART regimen in children 
exposed and not exposed to single dose NVP at birth. (Paper IV) 
 
 
 
Philippa M Musoke 
 
 28 
Study subjects and methods 
Study area 
The study was conducted in Uganda, a landlocked country located in East Africa 
bordered by Kenya on the east, Tanzania in the south, Sudan in the north and the 
Democratic Republic of Congo (DRC) on the west. It is a beautiful country on the 
equator covering 240,000 sq km with an average altitude of 1100 m above sea level. 
The climate is tropical with temperatures ranging between 15-30 °C with two rainy 
seasons per year.  
 
Uganda has a population of  ~32 million people and one of the highest fertility rates of 
7 children per woman and an infant mortality rate of 76 per 1000 live births [80]. The 
national HIV-1 seroprevalence has significantly reduced over the last decade and 
stands at 6.4 %. Currently there are a million people living with HIV-1 infection of 
which ~150,000 are children. Without access to PMTCT over 20,000 infants are newly 
infected with HIV-1 each year. 
 
 
Figure 5. Map of Uganda within the Arica and East African region. 
 
Kampala is the capital city of Uganda and has a population of ~2 million. Mulago 
hospital in Kampala is the largest national referral and University teaching hospital 
with > 1500 beds and multiple outpatient clinics. The paediatric HIV clinic linked to 
the Baylor College of Medicine and supported by PEPFAR has over 6900 infected 
children registered for care and treatment and 4000 on antiretroviral therapy. The 
PMTCT program based in the Mulago hospital antenatal clinics are supported by MU-
JHU and over 3000 HIV infected women are identified through the program each year. 
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The HIV-1 infected and exposed infants are linked to the comprehensive Baylor 
Uganda paediatric HIV care and treatment clinic.  
Study site 
Figure 6.The MU-JHU Research Collaboration Site. Top row – external view and 
bottom row: inside clinic, mother at dispensing window and nurse weighing infant.
The Makerere University – Johns Hopkins University (MU-JHU) research clinic is 
located in 3 double story buildings on the Mulago hospital complex campus and can 
refer study patients requiring inpatient services to the hospital (Figure 6). The research 
collaboration was started by investigators from MU and JHU who wanted to study the 
natural history of maternal and paediatric HIV-1 infection, and develop strategies to 
prevent MTCT in resource-limited settings. MU-JHU has been in existence since 
1988, involved in multiple perinatal HIV prevention clinical trials including the 
landmark HIVNET012 study which led to the use of sdNVP for prevention of MTCT 
in resource-limited settings [81, 82].  
 
In 2000, MU-JHU supported Mulago hospital to set up their PMTCT program, initially 
using sdNVP, but currently implementing more efficacious ARV regimens. Over the 
last 8 years MU-JHU has also provided comprehensive HIV care and treatment to 
women identified through the PMTCT program, as well as their infected partners and 
children.  
Philippa M Musoke 
30
Since 2003, the clinic has enrolled and followed >1000 adults and children in a 
comprehensive family HIV care and treatment program through the MTCT plus of 
Columbia University, New York [83]. Currently there are 800 participants in active 
follow-up with 500 on antiretroviral therapy including 150 children. The site also 
received the International Leadership Award (ILA) funded through Elizabeth Glaser 
Pediatric AIDS Foundation that enabled children to be initiated on ART, as early as 
2004, when there was limited access to ART in Uganda. The data for paper III and IV 
were from children initiated on ART in the ILA program. 
Currently the site is conducting multiple National Institutes of Health (NIH), 
International Maternal, Paediatric and Adolescent AIDS Clinical Trials (IMPAACT) 
network studies including P1060 whose primary objective was to determine the 
response to a NNRTI vs. a PI based regimen in children exposed and not exposed to 
sdNVP at birth. The majority of MU-JHU study participants live within a 20 km radius 
of the clinic. For the studies included in this thesis, the participants were enrolled from 
1997 to 2004 for the HIVNET012 study, and from 2004 to 2006 for the ILA ART 
study (Figure 7). 
  HIVNET 012 cohort (Paper I, II)           ILA cohort (Paper III, IV)
HIV-1 infected children     Infected children on  
       followed from birth to 60 months    ART for 48 – 96 weeks 
1997          2004           2006              2008
Figure 7.  Timeline for the studies included in the thesis.  
Methods 
All the studies included in this thesis utilized a prospective cohort design. The first 
cohort of HIV-1 infected children was followed from birth to 5 years of age (Papers I 
and  II) and the second cohort of  infected children was initiated on ART and followed 
for a minimum of 48 weeks ( Papers III and IV). The study population, design and 
analysis for the four papers are summarized in Table 5.   
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Study population for Paper I and II 
The participants for Paper I and II were HIV-1 infected children from an NIH Division 
of AIDS (DAIDS) perinatal HIV prevention clinical trial (HIVNET012) conducted at 
the MU-JHU clinic, Mulago Kampala [81, 82]. The trial was a randomized controlled 
clinical trial in HIV-1 infected women to determine the effectiveness of NVP to the 
mother at the onset of labour, and to her infant within 72 hours of delivery in 
preventing mother-to-child HIV transmission.  All the participants were enrolled into 
the study after providing written informed consent. 
 
Table 5. Summary of the study population, design and analysis for the different 
papers 
 
Paper 
 
 
Topic 
 
Study population 
 
Study design 
 
Analysis 
I Natural history 
of HIV infected 
Ugandan 
children 
HIV-1 infected 
birth cohort at 
the MU-JHU 
clinic, Kampala 
UG 
(1997 – 2004) 
N= 128 
Prospective five 
year cohort study of 
perinatally HIV 
infected children 
Univariate Cox regression model 
Mixed effects models for CD4 
and HIV-1 RNA 
Kaplan Meier estimates for 
survival since HIV acquisition 
Kaplan Meier estimates for time 
to event (hospitalization) 
 
II 
 
Use of the total 
lymphocyte 
count as a 
surrogate 
marker for risk 
of death 
 
Same as above 
 
Retrospective 
review of 
longitudinal TLC and 
CD4 cell count 
measurements from 
a prospective five 
year cohort of HIV 
infected children 
 
Partly conditional survival 
methods for CD4 cell counts, 
TLC and HIV-1 RNA 
Cox proportional hazard 
regression models 
ROC curves for sensitivity and 
specificity of TLC compared to 
WHO CD4 cell cut-offs 
 
III 
 
Growth, 
immune and 
viral response 
to antiretroviral 
therapy 
 
Cohort of HIV-1 
infected children 
initiating fixed 
dose 
combination 
ART (n=124) 
2004 - 2006 
 
Prospective cohort 
of HIV infected 
children initiating 
HAART and 
followed for 48 
weeks 
 
Primary endpoint was viral load 
<400 copies/ml and CD4% 
above severe immune 
suppression.  
Logistic and multinominal 
regression, univariate, 
multivariate  
GEE to analyze weight and 
height velocity 
 
IV 
 
Response to 
NVP based 
HAART in HIV 
infected 
children 
exposed and 
not exposed to 
sdNVP 
 
Same 
population as III 
but a sub-study 
N=94 (2004 – 
2006) 
 
Observational 
prospective cohort 
of HIV infected 
children initiating 
HAART and 
followed for 48 
weeks 
 
Primary endpoint was sustained 
achievement of viral load <400 
copies/ml 
K-M estimates of conditional 
probabilities of achieving 
endpoint at 48 weeks 
Cox regression analyses 
indicating hazard ratios 
associated with various baseline 
characteristics 
 
There were 654 HIV-1-positive women enrolled in the HIVNET 012 trial, 637 
delivered live born infants. Of the 617 delivered infants analysed, 128 (21%) became 
HIV-1 infected during the follow-up period with 10% testing HIV positive at birth. 
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The initial study duration was 18 months but it was extended to allow for 5-year 
follow-up of all infants to monitor long term safety of perinatal exposure to NVP and 
AZT. This enabled the close follow-up of a cohort of HIV-1 infected and uninfected 
children from birth until 5 years of age. 
Physical exam and laboratory assessment 
All infants had a medical history and physical examination at all the scheduled visits 
including birth and 7 days; 6, 10, 14 weeks;6 months and then every 6 months until 60 
months of age. Complete blood counts (CBC) and CD4%/counts were done at birth, at 
14 weeks, at 12 and 18 months and then every 6 months for those children who were 
HIV-1 infected. Qualitative HIV-1 RNA PCR assays were done at age 1-3 days, 6, 14 
weeks and 12 months. Quantitative HIV-1 RNA PCR was done at all subsequent visits 
for those found to be HIV-1 infected at the previous visit.
Statistical analysis  
Paper I
For this analysis the HIV-1 infected infants were divided into 2 groups, those who 
were HIV positive at birth and those who became infected later. The Cox regression 
model was used to determine association between maternal and infant characteristics 
and death from time of HIV-1 acquisition. Median CD4 percent and HIV-1 RNA over 
time from birth to 60 months was analyzed using the mixed effects model and 
presented as graphs. Kaplan Meier curves were used to estimate survival and time to 
event (hospitalizations) for the 2 groups. 
Paper II
A Cox proportional hazards regression model was used to estimate the risk of death 
within one year by CD4% and TLC. The models were adjusted for age at the time of 
the measurement. Probabilities of death within 1 year were calculated by estimating 
the baseline survival function by non-parametric maximum likelihood method from 
the predicted survival probabilities. Time-dependent receiver operator curves (ROC) 
for markers of mortality were estimated to evaluate the ability of CD4% and TLC to 
identify death within one year from the time of measurements. The sensitivity, 
specificity, PPV and NPV of the WHO TLC threshold relative to the WHO CD4% 
threshold for determining severe immune-suppression were calculated according to 
age groups (<12 months, 12–35 months, and >35–60 months). 
Study population Papers III and IV 
Study participants for paper III and IV were HIV-1 infected children from the Mulago 
Paediatric HIV clinic and MU-JHU Research clinic, Kampala, who were eligible for 
ART according to the WHO antiretroviral therapy guidelines 2002. The children were 
enrolled into the study after the parents/caretakers provided written informed consent. 
They were enrolled into a prospective observational study for a period of follow-up of 
24-96 weeks. A total of 130 children were enrolled and initiated on ART as part of the 
International Leadership Award (2003). A subset of them (94) were also enrolled in a 
study to determine the response to a NVP-based ART regimen in children exposed and 
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not exposed to single dose NVP at birth. Both cohorts were followed prospectively and 
after initiation of ART were seen at 2 and 4, weeks, and then every 12 weeks until 96 
weeks of age. CD4 cell counts/percents and HIV-1 RNA measurements were done at 
baseline and every 12 weeks until study end.  
 
Antiretroviral drugs, a fixed-dose combination of d4T, 3TC and NVP were prescribed 
and dispensed on a monthly basis. All the children had > 48 weeks of follow-up 
excluding those who died, and 60% of the children had 96 weeks of follow-up. 
 
Statistical analysis  
 
Paper III
The primary endpoint for this analysis was achievement of a viral load of < 400 
copies/ml at 24 weeks that was sustained through to 48 weeks, and achievement of 
CD4 cell count/percent above the level of immune suppression for age. The children 
were classified into treatment outcome groups: virological and immunological success 
(VS/IS), virological success and immunological failure (VS/IF), virological failure and 
immunological success (VF/IS) and both virological and immunological failure 
(VF/IF). Mean WAZ and HAZ scores at the different time-points of follow-up after 
ART initiation were compared using Scheffe’s multiple comparison test. Factors 
associated with treatment success were analyzed using logistic regression, and 
presented as univariate and multivariate analyses. Generalized estimating equations 
(GEE) were used to analyze weight and height velocity for different age groups during 
the 48 weeks of follow-up adjusting for various baseline factors.  
 
Multinomial logistic regression was used to determine factors associated with the 
different treatment outcome groups. All statistical analyses were assessed for statistical 
significance at the p < 0.05 alpha level.  
 
Paper IV 
The primary endpoint for this analysis was the sustained achievement of a viral load 
<400 copies/ml, and the analyses presented with reference to this endpoint are Kaplan-
Meier estimates of conditional probabilities of achieving the endpoint through 48 
weeks following initiation of HAART. Differences between Kaplan-Meier curves are 
assessed for statistical significance using the log-rank test. In addition, Cox regression 
analyses adjusting for, and indicating the hazard associated with the various baseline 
characteristics measured are presented. All statistical analyses were assessed for 
statistical significance at the p <0.05 alpha level. 
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Summary of results 
Paper 1 and II 
HIVNET 012 Study cohort 
In the HIVNET 012 study, there were 128 HIV-1 positive children identified, with 
52% female. Of these, 42 HIV-1 infected children (33%) died within the first 18 
months of life and 17 children died after 2 years of age, a total of 70 deaths over the 5 
year follow-up period (55%). Of the 499 HIV-1 negative children, 51% were female, 
and 26 (5%) and 35 (7%) infants died by 18 months and 5 years of age respectively. 
 
Paper I
Of the 128 infected children 59/128 (46%) were HIV-1 positive at birth (in utero 
transmission) and 69/128 (54%) became HIV infected later (postnatal transmission). 
There were 75/128 (59%) and 47/128(36%) infants exposed to intra-partum 
zidovudine and nevirapine, respectively. The total duration of study follow-up was 
4,468 child months, with a median follow-up time of 30.4 months (range 1.3-65.2) per 
child. The median CD4 cell count and HIV-1 RNA at delivery of 299 cells/mm3 (IQR 
170 -507) and 4.8 log copies/ml (IQR 4.5 -5.1), respectively. There were no significant 
differences in maternal characteristics for the infants in the 2 groups, except for a trend 
towards a higher median viral load at delivery in infants infected postnatally.  
 
The infants had a median birth weight of 3,025 grams and 10% had a low birth weight 
(<2500 grams). There were no differences in baseline infant characteristics between 
those infants who were positive at birth and those who became infected later, except 
for the duration of breastfeeding, 381 (CI 224-540) vs. 540 (CI 454-724) days, 
respectively. In the univariate Cox regression model, there were no maternal or infant 
factors significantly associated with death except maternal viral load at delivery (p= 
0.04). When stratified by time of HIV-1 acquisition, the Kaplan Meier estimates for 
survival from time of infection was similar in the 2 groups of children (p=0.17). The 
leading causes of death and hospitalization were pneumonia, diarrhoea and malaria. 
 
The median CD4% at birth was 42.6 % (IQR 31.6–51.6) and declined to 24.6% (IQR 
18.6–33.6) at 12 months, 19.3% (IQR 13.4-27.0) at 24 months and 20.1% (IQR 14.7-
26.1) at 60 months of age (Paper I, Table 3). By 12 and 24 months of age, 50% of the 
children had CD4% below 25% and 20%, respectively. At 60 months of age only 25% 
of the children had CD4 percents below 15%. The CD4% decline in both infant groups 
was similar and median HIV-1 RNA levels remained stable at a median of 5.5 log10 
copies/ml for the 60 months of follow-up. 
  
Paper II
In the first 18 months the median TLC in infected children ranged from 4150–5800 
cells per l, which was similar to HIV negative children whose median TLC range was 
4200–5600 cells per l. In contrast, the CD4% of HIV-1 infected children dropped 
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from a median of 41% to 19% compared to HIV-1 negative children whose median 
CD4% remained above 38% throughout this period.  
 
The risk of death within one year was assessed using the WHO recommended age-
specific TLC threshold values. The risk of mortality was highest for the youngest 
children at any given TLC threshold; for example, the 12-month risk of mortality at a 
TLC threshold of 3000 cells/l was 29% for infants aged 6 months compared to 11% 
at age 2.5 years. However, the 12-month risk of death did not significantly vary by the 
TLC threshold. TLC and CD4% were poor predictors of one year mortality for 
children under 12 months. CD4% and HIV-1 RNA were both significantly associated 
with the risk of death at a 95% confidence level. For example, decrease in CD4% of 
10% was associated with a 1.68 fold increase in risk of death and a one-log increase in 
HIV-1 RNA was associated with a 2.2 fold increase in risk of death. However, 
decreases of 1000 cells/l in TLC were associated with only a 1.1 fold increase in risk 
of death, and this HR was not significant.  
Paper III and IV 
ILA cohort 
A cohort of HIV-1 infected children aged 6 months to 13 years initiated on HAART 
using the 2002 WHO ART guidelines for resource-limited settings. Clinical and 
laboratory data from a total of 124 and 92 children were analyzed in paper III and IV, 
respectively.  
 
Paper III 
A total of 124 HIV-1 infected children with a median age of 5.0 years (IQR 2.1-7.0) 
and 61/124(49%) female were enrolled and initiated on HAART. The children were 
more likely to be stunted than underweight, with a median HAZ of -2.0 (IQR -2.9, -
1.2) and WAZ of -1.2 (IQR -2.1, -0.5) at baseline. The median CD4% and log10 HIV-1 
RNA were 11.75% (IQR 7.5–18.0) and 5.55 (5.2–5.8) copies/ml, respectively. On the 
basis of treatment outcome, the children fell into the following groups:  
 80 (65%) virological and immunological success – VS/IS  
 27 (22%) virological success and immunological failure –VS/IF  
 10 (8%) virological failure and immunological success – VF/IS  
   7 (5%) virological and immunological failure – VF/IF 
 
Of the children, 107/124(86%) had an undetectable viral load (< 400 copies/ml) and 
90/124(73%) had complete immune restoration after 48 weeks of HAART. By the end 
of the study, all the treatment outcome groups had a significant increase in mean 
growth z scores regardless of their virological and immunological treatment outcome. 
The overall mean WAZ and HAZ scores increased by 48 weeks from -1.14 (SD) and -
2.06 (SD) at baseline to + 0.6 (SD) and -0.41(SD), respectively (p=0.001). The VS/IS 
and VF/IS groups both had significant improvements in mean HAZ and WAZ scores 
on therapy, suggesting that complete viral suppression is not a requirement for an 
initial increase in weight and height (Fig. 1. Paper III). When the baseline 
characteristics were placed into a univariate model for association with the successful 
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treatment group (VS/IS) compared to the other treatment outcome groups, only CD4% 
at baseline was significantly associated with a successful treatment outcome. In the 
multivariate model, age and WHO clinical stage were also associated with a successful 
treatment outcome after adjusting for sex, HIV-1 RNA, CD4%, WAZ and HAZ.  
 
Paper IV
A total of 92 children fulfilled the study inclusion criteria and were enrolled into the 
study, with 44 in the sdNVP exposed group and 48 in the non-exposed cohort.  
Baseline demographic data was available for all 92 children, but only 90 children had 
baseline HIV-1 RNAs. The median duration of follow-up for all children was 72 
weeks (range 48–96 weeks). However, we only included time-points up to 48 weeks 
for this analysis where both cohorts had similar and complete data. Ninety-five percent 
(85/92) of all study children completed the 48 weeks of follow-up on HAART.  
 
The NVP exposed cohort was significantly younger than the NVP unexposed cohort 
(median 1.7 vs. 7.8 years, p = 0.38 [Table 2. Paper IV]. At baseline, the NVP exposed 
group had more advanced HIV disease (WHO stage III 54% vs. 2%) than the non-
NVP exposed cohort based on both virological and clinical assessment [Table 2. Paper 
IV]. However, as expected, the NVP exposed group which was younger, had a higher 
baseline CD4% (14% vs. 8.5%) compared to the relatively older NVP non-exposed 
group.  
 
At week 12, 24 and 48, the proportion of HIV-1 infected children with <400 copies/ml 
(virological treatment success) in those children exposed to sdNVP was 26/43(61%), 
34/42(81%) and 33/44(75%), respectively. In those children not exposed to sdNVP, 
virological success occurred in 29/45(64%), 34/45(76%) and 35/44(80%), at the same 
time-points [Log-Rank Test p-value =0.8 through 48 weeks (Figure 2. Paper IV)]. By 
48 weeks after HAART initiation, over 75% of both cohorts had a viral load <400 
copies/ml. In multivariate analysis, none of the baseline factors including sdNVP 
exposure had an effect on the outcome of virological treatment success (Table 3. Paper 
IV). 
 
Compared to the baseline, there was a significant and brisk increase in CD4% in both 
cohorts. The average trend of CD4% and absolute CD4 cell count response over 48 
weeks for the 2 cohorts are presented in (Figures 4a and 4b in Paper IV). In the NVP 
exposed cohort, the mean baseline CD4% was 14%, and there was a brisk and robust 
mean response in CD4% of 20 percentage points at week 48 on HAART. In the non-
NVP exposed cohort, the mean baseline CD4 percent was 8%, with a mean CD4% 
increase of 19% percentage points at 48 weeks. 
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Discussion
The overall aim of the studies in this thesis was to describe the natural history of 
paediatric HIV-1 infection, identify potential laboratory surrogate markers to predict 
death and document the early response to antiretroviral therapy in HIV-1 infected 
Ugandan children. All 4 papers used a prospective cohort design with 5 years (Papers I 
and II) and one year (Papers III and IV) of study follow-up.  
 
For Paper I and II, the parent study (HIVNET012) was a randomized clinical trial to 
prevent mother-to-child HIV transmission in HIV-1 infected Ugandan women. The 
HIV-1 infected children from this trial had longitudinal laboratory and clinical data 
collected over the 5 years. For Paper III and IV, the parent study was an observational 
cohort of HIV-1 infected children who were eligible for antiretroviral therapy. These 
infected children were followed for a minimum period of 48 weeks after initiation of 
ART and clinical and laboratory measurements including height, weight, CD4%/count 
and viral load were documented.  
 
This chapter will discuss the methodological issues of the different papers, the 
implications of the studies and overall conclusions drawn from the thesis. 
Study methodological considerations 
Paper I and II 
A prospective birth cohort is an appropriate study design to document the natural 
history of perinatally HIV-1 infected children and to assess the utility of laboratory 
surrogate markers for predicting risk of death in children from resource-limited 
settings. Cohort studies tend to have stronger evidence of causality and are less subject 
to biases due to selection, recall and measurement errors. The study design and 
analyses were appropriate for the objectives of the study, to determine the strength and 
degree of association of the TLC and CD4% measurements, and to check if a certain 
TLC cut-off could predict risk of death in the subsequent 12 months.  
 
The main limitation of the study was the high mortality in the first year of life leading 
to fewer data-points as the children became older. Survival bias may have occurred in 
this cohort of infected children because those children who survived beyond the first 
year of life were less likely to die and may have had higher TLC. In addition, the CD4 
% – the gold standard – does not predict death in children under one year of age, 
where there is a larger sample size and greater power to detect a difference. Most of 
the children had high TLC as has been reported in other African children, and so we 
were unable to correlate TLC and CD4% at the lower levels of TLC where correlation 
might have been higher. 
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Bias
All the children who became HIV-1 infected during the clinical trial were followed 
and had data available for analysis reducing the potential selection bias. However, 
those who survived had more data-points compared to those who died in the first year 
of life. In addition, the follow-up rates were very good with <5% loss to follow-up 
after 5 years so that there was no bias due to those in follow-up being different from 
those lost to follow-up. Measurement errors could results from laboratory 
measurements of HIV-1 RNA, TLC and CD4% and counts. To reduce the 
measurement bias, for example the diagnosis of HIV-1 infection in children was done 
using HIV-1 RNA PCR and a repeat test was done for those who were found to be 
PCR-positive. All the HIV infected children also had HIV-1 RNA measurements every 
6 months to monitor viral load over time. All the laboratory tests were standardized 
using quality assurance and controls as required for a CAP certified laboratory.  
 
Validity
The internal validity of the study was good because of the nature of the design and low 
loss to follow-up. The study also had external validity and could be generalized to 
other African HIV-1 infected children birth cohorts although our mortality rate may 
have been slightly lower because of the care provided for the children during the 
clinical trial. In addition, our results were consistent with cohorts of other African 
children enrolled in perinatal HIV prevention trials. 
Paper III and Paper IV 
The study design for both these papers was a prospective observational cohort of HIV-
1 infected children aged 6 months to 13 years, initiated on antiretroviral therapy and 
followed for a minimum of 48 weeks. The strength of this design was the longitudinal 
nature of the clinical and laboratory data collected over time with good follow-up rates 
ensuring that all children, except those who died had a similar follow-up period. The 
follow-up rates were high (98% Paper III and 95% Paper IV) in both groups, and this 
reduced the potential selection bias which could occur if there was a high loss to 
follow-up and unknown treatment outcome of a subset of the cohort. Despite being an 
observational cohort the choice of the longitudinal measurement of viral load and 
CD4%/counts as surrogate markers for good treatment outcome and is a reliable, 
standardized and previously reported method for documenting treatment outcome in 
HIV-1 infected adults and children. Therefore the results of this non-randomized trial 
could be compared to other treatment trials, with the caveat that there were significant 
baseline differences that could have affected treatment outcome.  
 
In this study (Paper IV), however, the sdNVP exposed younger children would have 
been expected to have a higher virological failure rate when compared to the older 
non-NVP exposed children, but the 2 groups had similar rates of virological 
suppression after 48 weeks of HAART. Another limitation was the short duration of 
follow-up (only 48 weeks for all children), we were not able to determine if the 
success in treatment outcome was sustained beyond the first year of therapy. 
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This observational cohort design had the potential for selection bias including 
differences in baseline characteristics which may affect treatment outcome. However, 
we attempted to control for confounders such as age, baseline viral load and CD4 cell 
count in the analysis by using logistic regression. A randomized controlled trial would 
have been a better study design with all children who were exposed to sdNVP being 
randomized to receive a NVP based HAART regimen or a non NVP based regimen. 
With a randomized study design the selection bias would be eliminated and the main 
difference between the 2 arms would be the treatment regimen received. However, we 
were unable to randomize children to exposure and non-exposure to sdNVP at birth, so 
this impacted the outcome of the results. The NVP exposed children were younger 
because the PMTCT program began in the year 2000, so all exposed children were 
below 4 years, and the non-exposed were older long term survivors.  
 
To reduce the confounding by age, that impacts both viral load and CD4%, we could 
have matched the sdNVP exposed children to the non-NVP exposed by age. Therefore 
we compared 2 different populations, which had baseline differences that could have 
affected the treatment outcomes. However, one would have expected the younger NVP 
exposed cohort, with a higher viral load and potentially higher levels of resistant 
mutations, to have had a higher virological failure rate. In our study the 2 groups (NVP 
exposed and non-exposed) were comparable in virological treatment outcome, and we 
attempted to control for confounders in the analysis by using logistic regression. The 
best study design would have been a randomized controlled study (P1060) where the 
baseline characteristics would be similar and controlled by randomization. This study 
was subsequently conducted at MU-JHU as part of a multicentre trial of the 
IMPAACT network, National Institutes of Health, USA. 
 
Implications of thesis findings 
Infant and child survival
Infant survival in resource-limited settings is highly dependent on the survival and 
health of the mother, because the mother not only provides adequate early nutrition 
through breastfeeding but also improves access to care and treatment [84]. In our 
cohort of HIV-1 infected children (Paper I), the maternal viral load at delivery was 
associated with infant mortality, consistent with previous reports [39]. A higher viral 
load is found in women who are sicker and may not be able to provide adequate 
nutrition through their breast milk and/or adequate care and treatment for their infants. 
Maternal mortality was not associated with infant mortality in our study, but this is 
probably due to the small sample size and the few maternal deaths during the first 18 
months of follow-up. Unlike adults with HIV-1 infection, infected infants may die 
regardless of the degree of immune suppression, with no specific risk factors 
identifying those at highest risk of dying [85]. Without access to ART, the provision of 
routine care and treatment for acute illnesses, immunization and nutritional support do 
not significantly improve the overall survival of HIV-1 infected children. The frequent 
and severe infectious diseases, poor response to treatment of common childhood 
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illnesses, underlying severe malnutrition and limited access to health care leads to a 
high mortality rate in HIV-1 infected children [5]. 
 
Most studies have reported a higher mortality rate in children infected in utero 
compared to those infected postnatally through breastfeeding [30, 86] The recent 
pooled analysis and mathematical modelling by Marston et al of the net infant and 
child survival from multiple perinatal HIV prevention trials in Africa showed a much 
higher mortality rate for infants infected perinatally compared to those infected 
postnatally through breastfeeding [86]. Our study (Paper I) showed a slightly higher 
mortality rate in children infected in utero compared to those infected later, but this 
difference did not reach statistical significance. The findings from our study were 
similar to the pooled analysis with the in utero infected children having a higher 
mortality rate than those infected postnatally, but because of the small numbers, the 
study lacked the power to detect a significant difference between the 2 groups. In 
addition, the classification of the perinatal/in utero vs. postnatal infection groups in our 
study was different from the definition in the pooled analysis. Those infants who were 
infected in utero, but had a negative HIV test at birth, were classified as postnatally 
infected in our study and this may have affected the overall mortality in the postnatal 
group. In the pooled analysis, the perinatally infected group included those infants 
infected in utero (HIV-1 positive a birth) as well as those infants who became infected 
during the first 4 weeks of life. The infants in our study had a much lower mortality 
with one year survival of 0.68 and 0.82 in the in utero and postnatal groups compared 
to 0.49 and 0.76 in the pooled analysis groups, respectively [86]. The lower mortality 
rate in our study cohort may be related to the specific clinical care and treatment 
provided to the infants in our study and the regional differences in infant mortality.  
 
Regardless of the timing of HIV-1 infection, the infected African infant has an 
unacceptably high mortality. The CHER trial conducted in South Africa demonstrated 
a significant reduction in mortality when HIV-1 infected infants were initiated on ART 
within the first few months of life [87]. From this data and other studies, WHO now 
recommends that all infected children below 2 years of age should be initiated on ART 
regardless of CD4 cell count or HIV clinical stage [6].  
 
Surrogate markers of disease progression and death
The CD4 cell count is a predictor of death in infected adults and older children but 
access to CD4 cell counts is not always readily available in many resource-limited 
settings [88-90]. Simple laboratory tests including haemoglobin, albumin, p24 Ag and 
total lymphocyte counts were considered potential surrogate markers for disease 
progression and death for resource-limited settings [85].  However, in resource-limited 
settings several studies including our own Paper II have found that TLC did not 
correlate with CD4 cell count and could not be used as a surrogate marker for 
CD4%/count or to determine those infected children at highest risk of death [91, 92]. 
Because of the high background mortality rate in children under 2 years, many 
infected children die before there is evidence of severe immune suppression, decreased 
TLC or advanced HIV-1 disease. In addition, African children tend to have a lower 
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white cell count, but have a higher total lymphocyte count, leading to poor correlation 
of TLC and CD4 cell count [93, 94]. In view of the accumulated data about the poor 
correlation of TLC and CD4% in resource-limited settings, the WHO ART guidelines 
were revised to exclude the TLC. In addition, they recommend that all HIV-1 infected 
children below 2 years of age should be initiated on ART regardless of CD4% or 
clinical staging, and the CD4 cell cut-offs for initiating ART in older children were 
lowered [6]. These changes in the guidelines of when to initiate ART in children 
should lead to children initiating ART prior to severe immuno-suppression; which 
would improve overall ARV treatment outcomes [57]. 
 
Table 6. WHO Antiretroviral therapy guidelines [6] for initiation of ART in 
children 2010[6]. 
Immune marker Age-specific recommendation to initiate ART 
  <24m 24 - 59m >5 yrs 
CD4 percent All <25%  
CD4 count/mm3 All <750 cells <350 cells 
Clinical criteria for ART = WHO clinical stage 3 and 4 
 
These findings regarding the utility of the TLC in resource-limited settings suggest 
that some strategies for monitoring HIV-1 infected children in resource-rich countries 
cannot be directly transferred to resource-limited settings without prior validation. 
Therefore different strategies are needed to identify children at highest risk of death 
and to monitor disease progression and response to ART in resource-limited settings.
Antiretroviral therapy and growth
Antiretroviral therapy improves the survival, growth and overall quality of life of HIV 
infected children [3, 95-98]. The delay in initiating ART is associated with poorer 
immune and growth responses and subsequent higher rates of virological failure [59]. 
Despite incomplete viral suppression on ART, many children gain weight and their 
immune recovery is maintained for a period of time [58]. Our study findings (Paper 
III) were consistent with other reports where complete viral suppression on ART was 
not a prerequisite for growth and immune response in children [59, 99]. In our study 
(Paper III), the older children were less likely to have a significant increase in height 
and the younger children had a more robust growth response on ART, despite 
incomplete virological suppression. Incomplete viral suppression with adequate 
growth and immune restoration in children on ART may be acceptable in resource-
limited settings where there are limited treatment options including access to more 
expensive second line ARV regimens [58]. The challenge of persistent viraemia on 
ART is the emergence of drug resistant virus, which ultimately leads to immunological 
and clinical failure with further limitations in second line treatment options [100, 101].  
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HIV drug resistance after exposure to sdNVP at birth
Exposure to sdNVP at birth leads to emergence of NVP resistant mutations in about 50 
% of the HIV-1 infected infants [68, 102].  The emergence of resistance mutations 
after exposure to sd NVP at birth may impact future treatment options with a NVP 
containing regimen. In our study of 92 children (Paper IV) with a median age of 1.7 
years, sdNVP exposed and non-exposed children had a similar virological treatment 
response to a NVP containing ART regimen.  However, in the P1060 study, 
subsequent treatment with a NVP containing ART regimen in sdNVP exposed  infants 
lead to higher virological failure rates after 24 weeks of therapy compared to those 
children who received a PI-based regimen [70]. The P1060 study was a prospective 
cohort study HIV-1 infected ART naive children who were NVP exposed (cohort 1) 
and non-exposed (cohort II). They were randomized to receive a NVP based regimen 
or a Lopinavir/ritonavir based ARV regimen. In both cohorts the NVP based regimen 
had higher virological failure rates (40.1% vs. 18.6% p=0.001) when compared to the 
PI-based regimen [70]. This difference may be related to the younger age of children 
enrolled in the P1060 study compared to our study children. In this randomized 
clinical trial, despite higher virological failure rates in those children on a NVP based 
regimen there were some children who were exposed to sdNVP and did respond to the 
NVP based regimen [70]. In our study (Paper IV), older children (median age 7.8 
years) on a NVP-containing regimen had similar virological success rates to those 
children (median age=1.7 years) who were exposed to sdNVP at birth. This is 
consistent with fading of  the resistant virus over time, with the older children having 
their virus revert back to wild-type virus, which would be sensitive to NVP [68]. In 
contrast to the randomized controlled trial where the majority of the children were 
below three years of age, our small observational cohort (Paper IV) had older children 
who were less likely to still have resistant virus and would therefore be more likely to 
respond to a NVP containing regimen.  
 
It is not possible to predict which sdNVP exposed child will have virological success 
on a NVP-based regimen unless one has access to HIV resistance testing, not currently 
available in most African countries. Therefore WHO ART guidelines for infants and 
children recommend that all infants exposed to sdNVP should be initiated on a PI- 
based regimen [6]. LPV/r, the PI available in most resource-poor settings, is expensive 
and more difficult to administer in younger children, where the syrup formulation had 
a short shelf-life unless refrigerated and the Alluvia® tablet cannot be crushed 
(Lopinavir/ritonavir package insert). Because PIs are not readily accessible in some 
African countries, infected children under 2 years of age do not have access to the 
WHO recommended first line ART regimen. Our study findings and other reports 
suggest that those children who were exposed to sdNVP should not be denied access to 
ART, when PIs are not available, because some children may still have a successful 
treatment outcome on a NVP based regimen.  
 
A strategy which could be used in resource-limited settings to spare the PIs for second 
line therapy, would be to initiate NVP exposed infants on a PI-based regimen and then 
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later switch to a NNRTI, when the children have achieved complete viral suppression 
and potentially  the NNRTI resistance mutations would have faded. A recent 
randomized controlled trial of switching to a NVP based regimen after initiating a PI 
based regimen in children exposed to sdNVP at birth found that a greater number of 
children had a viral load < 50 copies/ml after 52 weeks (p=0.02), in the switch group 
compared to those children who stayed on the PI regimen [103]. However, the switch 
group had more children with a viral load >1000 copies/ml. Therefore, this treatment 
strategy may be useful in protecting the PI regimens for future second line therapy in 
resource-limited settings. 
 
As well as providing care and treatment for HIV-1 infected children, there is an urgent 
need to prevent more infants from becoming infected. The ultimate solution for 
paediatric AIDS is to eliminate mother-to-child HIV transmission through the scale-up 
of PMTCT programs in resource-limited countries, in order to significantly reduce the 
number of infants newly infected each year. We have the knowledge and skills 
required to scale-up PMTCT services, but implementation has been limited with <50% 
of pregnant women accessing PMTCT services worldwide (1). The UN agencies have 
committed themselves to the virtual elimination of paediatric HIV-1 infection, which 
is <5% transmission of HIV from mother to infant. Currently, most ART and PMTCT 
services in African countries are highly dependent on donor support including Global 
Fund for TB, HIV and malaria, and PEPFAR. It is not clear what strategies individual 
countries have planned for the sustainability of these programs and services. Universal 
coverage will only be achieved if resource-constrained countries can make a political, 
civil society and individual commitment to provide, monitor, integrate and utilize the 
infrastructure for PMTCT services including improvement of the overall maternal and 
child health services.  
Policy implications 
The findings from these studies have significant policy implications and highlight the 
importance of conducting locally relevant paediatric HIV research that can inform 
WHO and national HIV/AIDS policy. The natural history and mortality data (Paper I) 
are very important for developing better understanding of the pathogenesis of 
paediatric HIV-1 in Africa (Paper I). This study is no longer ethical in the era of ART 
and yet the data provides information that can be used to develop innovative strategies 
to improve paediatric HIV care and treatment in resource-limited settings. The very 
high mortality rate in children and additional studies documenting the benefit of early 
ART in infants has led the WHO to recommend initiation of ART in all HIV-1 
infected children under 2 years of age, regardless of CD4% or WHO clinical stage. 
The findings of poor correlation between TLC and CD4% (Paper II) were consistent 
with a large study from Africa, and informed WHO policy to withdraw the TLC from 
the immune criteria for ART initiation in resource-limited settings. These 2 studies 
highlight the urgent need to implement strategies to prevent common childhood 
illnesses by providing access to pneumococcal and rotavirus vaccines. In addition, 
national scale-up of PMTCT services and early infant HIV diagnosis is essential for 
identification of infected infants and referral for appropriate care and treatment. 
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Most children who initiate ART gain weight rapidly even if they fail to completely 
suppress the virus. Therefore, weight gain alone may not determine treatment success 
in HIV-1 infected children on ART as most children continue to gain weight and 
maintain a high CD4%, despite virological failure. In rural settings, however, weight 
gain may be the only measurement that is feasible for documentation of early 
treatment response when CD4% and viral load monitoring are not accessible. The 
WHO currently recommends use of weight as a surrogate for treatment response in 
centres where CD4% testing is not available [6]. Simple point of care CD4% tests are 
urgently needed to monitor treatment response in resource-limited settings. 
 
After release of the P1060 results which demonstrated that a PI-based ART regimen in 
NVP exposed infants was superior to a NVP based regimen, WHO now recommends 
that all NVP exposed infants should initiate ART with a PI-based ART regimen. It is 
important to note that about 60% of the children on the NVP based regimen had a 
successful treatment outcome with an undetectable viral load at 24 weeks after ART 
initiation. In addition, our data (Paper IV) demonstrated similar ARV treatment 
response in older children exposed and non-exposed to sdNVP at birth. Therefore, in 
resource-limited settings the use of a NVP based regimen in NVP exposed infants may 
be considered when PI regimens are unavailable. 
 
The ultimate solution to paediatric HIV-1 infection in resource-limited settings is for 
countries to make a commitment to scale-up PMTCT services in order to reduce the 
number of newly infected infants, identify infected infants early and refer them for 
initiation of ART.  
 
Future research
Developing simple surrogate markers to determine risk of disease progression and 
death in resource-limited settings are still needed. A simple point of care (POC) test to 
predict children with the highest risk of dying is urgently needed where the CD4 cell 
counts are not available. When older children who are stunted are not initiated on ART 
until eligible, they tend to remain stunted and do not achieve physical maturity despite 
treatment. Therefore research to determine if the earlier initiation of ART in older 
children who are stunted, but not yet eligible for ART, could improve growth and 
maturity remains a priority. Data on the long term outcomes of ART in children from 
resource-limited settings, including growth, cognitive development and puberty is still 
needed. In addition, documenting long term complications of ART in resource-limited 
settings is still needed including the development of strategies to prevent or reduce the 
complications of ARV drugs. 
 
Developing simplified regimens, additional paediatric ARV fixed-dose combinations 
and simple strategies for ART delivery and the monitoring of children remains a 
priority for the future sustainability of ART programs [104]. Simple POC tests to 
measure viral load could include above or below a certain threshold so as to develop 
an appropriate cut-off level as opposed to specific HIV-1 RNA copies/ml. A cut-off of 
<5,000 copies/ml or <10,000 copies/ml and >100,000 copies/ml would be ideal to 
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monitor those on ART. Strategies to improve adherence in older children are still 
needed in the community including the setting up of adherence-support peer groups 
and age appropriate motivational rewards for good adherence. Operational research to 
improve delivery of paediatric services and retention in care and treatment should be 
considered including innovative strategies for service delivery. In the future, 
innovations such as ARVs administered orally or parentally once a month would be 
useful for older children who struggle with adherence. A life-time of treatment is 
difficult in a high-income country, but almost impossible in resource-constrained 
settings, unless different strategies are employed. Development of simplified ART 
regimens and delivery services, utilization of family and community support for ART 
including PLA, implementation of innovative strategies for adherence, is critical for 
the scale-up of ART in Uganda, in an already overloaded health care system.  
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Conclusions
1. HIV-1 infected Ugandan children had a very high mortality rate during the first 
two years of life regardless of the time of HIV-1 acquisition, and no specific 
maternal or infant factors could predict death except the maternal viral load at 
delivery. 
 
2. The total lymphocyte count is not a surrogate marker for the risk of death in the 
first 12 months for HIV-1 infected Ugandan children, and is not useful in 
determining which children are at risk of death and in urgent need of ART. 
 
3. Early initiation of ART, at a young age and prior to severe immuno-
suppression, is critical for ensuring adequate growth and an immune response in 
HIV-1 infected children. However, complete viral suppression is not a 
prerequisite for adequate early growth and immune responses on ART. 
 
4. Older infants and children had an adequate response to a NVP containing ARV 
regimen despite exposure to sdNVP at birth, suggesting that NVP based ART 
may still be an option for older children, even if they were exposed to 
nevirapine at birth. 
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ERRATA LIST 
On page 21 Figure 2 was:  
Should read (and have been replaced with): 
